The Global Health Body Raises Warning Over Acute Lack of Obesity Jabs

Under 10% of patients that would benefit from obesity jabs such as Wegovy have access to them, states the WHO as it issues its initial guidance on the medications.

Considering more than one billion individuals worldwide now living with obesity, it is urging more widespread and fairer availability to this class of drugs.

Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.

"The latest guidance affirms that obesity is a chronic disease that can be managed with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major hurdles to broad access to the jabs that can aid individuals in losing substantial body mass, notes the agency.

Weight-Loss Drug Shortage

Despite the present most optimistic case, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization.

The recommendation encourages nations and manufacturers to widen availability, through strategies like patent sharing.

A patent on semaglutide – the primary component of the drug Wegovy – is due to expire in a number of nations in 2026.

How Obesity Jabs Function

The injections mimick a biological compound to slow digestion, reduce hunger and enhance the sense of being full so people eat less.

People typically see weight reduction after several weeks of starting on the once-weekly jabs.

Studies indicates people may put most of the weight back on after a year of stopping the treatment, because their normal hunger return.

Being overweight or obese raises your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.

Excess weight concerns people in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the WHO.